Ichor CEO Delivered Lysoclear Update and Held Workshop at Annual LEAF Conference

Posted Posted in Icaria Life Sciences, Ichor, Lysoclear

12 July 2019  NEW YORK, NY: The second annual Life Extension Advocacy Foundation (LEAF) Ending Age Related Diseases Conference was held in New York City July 11-12th. This conference brought together many of the top minds in the biotechnology rejuvenation field, including Dr. Kelsey Moody, CEO at Ichor Therapeutics, Inc. Dr. Moody also held a workshop prior to the conference, on July 10th.   The workshop was held in the Cooper Union […]

Ichor’s Jacob McAndrew takes 6th in JP Morgan Corporate Challenge

Posted Posted in Ichor

On May 21st, 2019 ten Ichor employees participated in the JP Morgan Corporate Challenge at Onondaga Lake Park. The Ichor team ran 3.5 miles (5.6km) alongside many other local companies in order to raise money for the non-profit organization, Syracuse Stage, while encouraging health and fitness in the workplace, camaraderie amongst employees, and promoting an overall environmentally friendly lifestyle. At this event, Jacob McAndrew, Operations Manager of Cell Biology at Ichor Therapeutics, Inc., placed 6th out of 5,000 participants, with a time of 19:01.

Ichor’s Auctus Biologics Closes Quick $1.5MM

Posted Posted in Auctus Biologics, Ichor

Auctus Biologcs, Inc., a new portfolio company of Ichor Therapeutics, Inc., announced today the closure of $1.5MM in seed funding. The company will develop RPtag, a hyper-stable antibody mimetic scaffold published earlier this year in the peer-reviewed journal ACS Biochemistry, to take on conventional clinical antibody therapy as an orally bioavailable formulation. New high priority immunosenescence and gastrointestinal targets will also be pursued.

Ichor Portfolio Company, Antoxerene, Closes $10MM Deal with Juvenescence

Posted Posted in Antoxerene, FoxBio, Ichor

Antoxerene, Inc., a portfolio company of Ichor Therapeutics, Inc., focused on small molecule drug discovery for pathways of aging, announced today the launch of a joint venture with Juvenescence Limited. The joint venture, called FoxBio, Inc., will develop Antoxerene’s collection of small molecules that target senescent cells. Juvenescence will support the venture with $10 million in equity financing and drug development expertise.

Industry Leader Joins Ichor Therapeutics as Chief Medical Officer

Posted Posted in Antoxerene, Ichor, Lysoclear

Ichor Therapeutics, a pre-clinical contract research organization, recently announced the appointment of Cornelis (Cees) Hendrik Wortel MD, PhD to the position of Chief Medical Officer (CMO). Dr. Wortel brings over 25 years of experience to Ichor, having worked as a senior (bio) pharmaceutical executive for early stage and established companies, both nationally and internationally. Most notably, he has been involved in the development of Remicade® (the first anti-TNF biological drug) and in a very large number of clinical trials, Phase I to IV, bringing innovative first-in-class drugs to market.